Integra LifeSciences Corp - רווח נקי למניה אחת בשנים עשר החודשים האחרונים IART

Integra LifeSciences relies on non-cyclical demand in neurosurgery with high macroeconomic resilience. The annual percentage change in EPS TTM on the GURU.Markets chart demonstrates current trends, where 103.00 characterizes this valuation parameter. Unique patents and strict certification create high barriers to entry, while the stabilization of production capacities ensures a reliable inflow of operating capital.

Amidst fierce competition with medtech giants for clinic budgets, the ability of Integra LifeSciences (IART) to maintain margins is critically important. This metric measures the percentage change in net income per share over a rolling year, allowing for an assessment of real business efficiency and the risk of overpaying for the asset, which is clearly reflected in the annual EPS TTM price action.